News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

TVM Life Science Ventures VII Announces First Investment: Kaneq Bioscience Ltd.

1/22/2013 11:30:29 AM

Montreal, Canada, January 22, 2013 / B3C newswire / - TVM Life Science Ventures VII today announced an investment into Kaneq Bioscience Ltd. based in Montreal, Quebec. This company is a spin out of Kaneq Pharma Inc., a biotechnology company developing early stage compounds for metabolic diseases and cancer. Kaneq Bioscience Ltd. was specifically created to develop a protein tyrosine phosphatase1B (“PTP-1B”) inhibitor for treating type 2 diabetes mellitus. “Other approaches targeting PTP-1B have shown efficacy in the clinic but oral small molecules have remained elusive. Our compound has promise as an orally active insulin sensitizer that can be paired with existing therapies.” stated Dr. Daniel Bouthillier, CEO of Kaneq Pharma Inc., who has joined Kaneq Bioscience Ltd. as Executive Chairman. Dr. Cynthia Lavoie, General Partner of TVM Capital Life Science and Board Member of Kaneq Bioscience Ltd. adds: “We are pleased to collaborate with Kaneq Pharma to create a company in Montreal which addresses a huge market need for diabetes patients”.

This is the first investment for TVM Life Science Ventures VII, a life sciences venture fund domiciled in Montreal QC, which follows a new investment approach to developing pharmaceutical assets to a human proof-of-concept in single asset companies. This approach has proven to be highly capital efficient through a high degree of outsourcing while creating an opportunity for faster exits through a trade sale to a pharmaceutical player looking to build its pipeline without having to take on legacy companies around the products that appeal to them.

Kaneq Bioscience Ltd. will tap into the rich ecosystem of service providers in the area to bring its asset to human proof-of-concept, including expertise provided by Montreal-based Chorus Canada, an offshoot of global-early-phase drug development network Chorus, an autonomous unit of Eli Lilly and Company. The company is also benefitting from the involvement of Kaneq Pharma management, a highly experienced team with complementary skills in pharmaceutical development.

About TVM Capital Life Science

TVM Capital Life Science is providing venture capital to the international pharmaceutical, biopharmaceutical and medical technology industries with more than 25-years of transatlantic investment track record and in excess of US$1.1bn under management. The Life Science Investment Group’s mission is to invest in the development of exciting early stage drug candidates and companies in the medical field that are or aspire to be innovative leaders in their market segment. Since 1984, TVM Capital Life Science made 116 investments in life science companies in Europe and the United States and exited from 85 companies, including 41 initial public offerings on the NASDAQ, and the London, Frankfurt, Zurich and Vienna Stock Exchanges and 25 trade sales and mergers. The Life Science team combines long-standing international investment and company building experience with their track record of dedicated board work, extensive global networks in the world of life science research and product development and a direct knowledge of the local markets. TVM Capital Life Science currently invests from its 7th fund generation, TVM Life Science Ventures VII, with an integrated team of investment professionals based in in Montreal and Munich. More information:; or twitter: tvmcapital

General Partner

TVM Life Science Ventures VII (GP) Ltd.

11-15 Seaton Place,

St Helier, Jersey

JE4 0QH, Channel Islands

Investment Advisor

TVM Life Science Management Inc.

2 Place Alexis Nihon, Suite 902

3500 Blvd De Maisonneuve West, Westmount,

Montréal, QC H3Z 1X5 Canada

About Kaneq Bioscience

Kaneq Bioscience Ltd, Montreal, is a spinout of Kaneq Pharma, a discovery and early development stage pharmaceutical company formed by former employees of the Merck Frosst Center for Therapeutic Research. This group has extensive drug discovery experience and has been intimately involved in the discovery of several marketed drugs plus novel therapies for hypertension and diabetes currently in clinical development. The focus of Kaneq Pharma is the delivery of high value molecules for validated targets in the areas of metabolic disease and cancer.


TVM Capital Life Science:

Dr. Cynthia Lavoie

General Partner

Phone: 514-931-4111

Dr. Hubert Birner

Managing Partner

TVM Capital Life Science

Phone: 514-931-4111

Kaneq Bioscience Ltd.

Dr. Daniel Bouthillier

Executive Chairman

Phone: 514-402-1764

Read at

comments powered by Disqus